CD7 and acute lymphoblastic leukemia: The main finding to emerge from this study is that [poly (I:C)] administered i.v. to SCID mice xenografted with a disseminated human T-ALL cell line significantly increased the therapeutic effectiveness of the anti-CD7 HB2-SAPORIN IT, leading to a 100% cure rate in the [poly(I:C)]/IT combination treated animals.